Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $63.66 USD
Change Today +0.69 / 1.10%
Volume 511.0K
As of 5:15 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

St. Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

of pain signals to the brain and inhibits or blocks the sensation of pain felt by the patient. Neurostimulation for chronic pain is used to manage intense and constant pain arising from nerve damage or nervous system disorders referred to as neuropathic pain. The company offers a range of neurostimulation systems for chronic pain, including rechargeable and primary cell IPGs and a complement of both percutaneous and surgical leads. The company markets various SCS neurostimulation product platforms worldwide, including the new primary IPG systems, such as Prodigy IPG with Burst Technology and Protégé with Upgradeable Technology. The company’s proprietary Burst Technology offers intermittent ‘bursts’ of stimulation designed to mimick the natural firing patterns of the brain. Burst has been shown to provide clinical superior results for various patients. In addition, Burst stimulation results in a reduction or complete elimination of the paresthesia sensation, which could result in undesirable changes in stimulation intensity with posture and body position changes. In combination with the company’s range of IPGs, it markets various leads, which are intended to enable clinicians to tailor the system to each patient’s needs. The company’s leads could be divided into three categories, such as percutaneous leads, paddle leads, and perc-paddle leads. The company’s percutaneous leads consist of the 8-contact Octrode and 4-contact Quattrode lead designs. The company’s paddle lead offering consists of the Lamitrode family of leads. This family includes single and dual column paddle leads that provide up to two vertebral segments, as well as lateral coverage; Tripole leads, which feature a three-column electrode array and are designed to focus stimulation to target low back pain; C-Series leads, shaped to mimic the curve of the epidural space of the spine and designed to facilitate lead placement and reduce lead migration; and the major Penta lead, a 5-column lead designed to provide stimulation control and specificity for focused stimulation therapy. Perc-paddle leads are a category of leads pioneered by the company with the advent of the Epiducer lead delivery system (European launch in 2010 and FDA approval in 2011). The Epiducer system is primarily designed to allow the percutaneous introduction of the company’s small profile S-Series paddle leads. S-Series leads are designed to have the focused stimulation and stability of a paddle lead yet, with the Epiducer lead delivery system, could be introduced through a minimally invasive percutaneous procedure. The company’s SCS systems are programmed with its Rapid Programmer platform. This system enables clinicians to test patients intra-operatively and program patients post-operatively. The Rapid Programmer platform consists of a palm-sized programmer that features a touch screen interface enabling clinicians to create multiple programs tailored for each patient's pain pattern. Using the foundation of the company’s Dynamic MultiStim technology for real time adjustments of multiple pain areas simultaneously, it simplified the programming of multi-focal pain by introducing MultiSteering technology. In addition to SCS, the company acquired NT Holding Company in 2014 adding RFA to the company’s chronic pain therapy portfolio of products. RFA could also be utilized to treat chronic spinal pain along with various peripheral areas that are not well treated with neurostimulation therapy. RF nerve ablation (also known as RF neurotomy) is an interventional therapy that employs heat to disable pain-transmitting nerves. The procedure is used for the treatment of various chronic pain syndromes. With RFA, the company could access chronic pain patients earlier in their treatment continuum. Neuromodulation could also be used to treat other neurological conditions. DBS involves the placement of a lead or leads in targeted areas of the brain. The company entered the DBS market in Europe to treat the symptoms of Parkinson's disease, a neurological disorder that progressively diminishes a person's control over movement. It also gained European CE Mark in 2013 for dystonia. This regulat


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $63.66 USD +0.69

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Edwards Lifesciences Corp $165.12 USD +1.45
Olympus Corp ¥4,945 JPY +30.00
Smith & Nephew PLC 1,121 GBp -12.00
Terumo Corp ¥3,980 JPY -20.00
Zimmer Biomet Holdings Inc $101.00 USD -0.29
View Industry Companies

Industry Analysis


Industry Average

Valuation STJ Industry Range
Price/Earnings 18.1x
Price/Sales 3.2x
Price/Book 4.5x
Price/Cash Flow 16.3x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at